Daily Pharma News - 14 October 2026

Welcome to PharmacoLearn's daily pharma news update for 14 October 2026. Today's headlines are dominated by drug price transparency in India -- with the Supreme Court, the Union Health Ministry and the Karnataka government all moving on the same day -- alongside two landmark US FDA drug approvals, a WHO milestone for tuberculosis research, and China's latest advance in cancer immunotherapy.

Supreme Court questions drug price caps limited to cancer drugs

The Supreme Court of India on 12 October asked the Union government why drug price regulation in the country is limited to cancer drugs, observing that steep markups exist across the entire medicine and medical device market. The Court cited the striking example of a coronary stent with a supply price of around Rs 5,000 being sold to patients at Rs 25,000 -- a five-fold markup that the bench found unacceptable.

The observation matters deeply for pharmacy students studying the Drugs (Prices Control) Order and the role of the National Pharmaceutical Pricing Authority (NPPA). Price caps under the DPCO currently cover scheduled formulations listed in the National List of Essential Medicines, but a large share of stents, implants and newer medicines sit outside strict ceilings. The Court's direction signals that the Centre may soon have to justify -- or expand -- the scope of price control across all therapeutic categories. The next hearing is scheduled for 27 October, and every pharmacy student should track this case as a living lesson in pharmaceutical jurisprudence and drug regulatory policy.

Union Health Ministry urges hospitals to display treatment rates

In a parallel push for transparency, the Union Health Secretary wrote to all states and Union Territories on 12 October, urging hospitals to prominently display their treatment and facility rates. The advisory aims to make billing visible to patients before admission and reduce disputes over hidden charges.

The Association of Indian Medical Device Industry (AiMeD) responded by seeking transparency across the medical device supply chain as well, arguing that device pricing should be traceable from the manufacturer to the hospital shelf. For pharmacy practice students, this story connects directly to hospital pharmacy management, procurement markups and the ethics of patient billing -- topics that frequently appear in B.Pharm and M.Pharm examinations and in real-world community and hospital pharmacy practice.

Karnataka to mandate landing price, MRP and charged price on hospital bills from November 1

Karnataka has gone a step further. From 1 November 2026, hospitals in the state must print three figures on every bill: the landing price, the MRP, and the price actually charged to the patient for each medicine, medical device and implant. Patients who are overcharged will be able to file complaints through a QR code printed on the bill itself.

This is one of the strongest state-level transparency measures in Indian healthcare and a textbook case study for pharmacy students in pharmaceutical marketing, MRP regulation and consumer protection. If you are studying how margins inflate between the distributor, stockist, hospital pharmacy and the patient, Karnataka's model gives you a real-world policy to reference -- and other states may well follow.

FDA approves Hovilpri (pritelivir): first new herpes drug class in 30 years

The US Food and Drug Administration on 9 October approved Hovilpri, the brand name for pritelivir, for treatment-resistant herpes simplex sores in immunocompromised adults. It is the first new herpes drug mechanism in roughly 30 years -- a helicase-primase inhibitor, unlike older drugs such as aciclovir, valaciclovir and famciclovir, which all work as nucleoside analogues targeting viral DNA polymerase.

This is a landmark moment in antiviral pharmacology. Pritelivir blocks the viral helicase-primase complex, an enzyme the herpes virus needs to unwind and copy its DNA, and it remains effective where nucleoside analogues fail because of resistance. For pharmacy students, Hovilpri is now the essential case study of a genuinely new antiviral mechanism of action -- expect it in pharmacology MCQs, GPAT questions and clinical pharmacy discussions on antiviral resistance in immunocompromised patients. The drug was developed by Asahi Kasei Pharma.

FDA approves WELTRUZA: once-monthly long-acting olanzapine injection for schizophrenia

On the same week, the FDA approved WELTRUZA, a once-monthly long-acting injectable formulation of olanzapine, developed by Medincell and Teva, for the treatment of schizophrenia in adults. The US launch is planned in the fourth quarter of 2026.

Long-acting injectable antipsychotics are a cornerstone of modern schizophrenia management because they solve the single biggest problem in the disease: poor adherence to daily tablets. Olanzapine is a second-generation (atypical) antipsychotic and a dopamine D2 and serotonin 5-HT2A receptor antagonist. Packaging it as a monthly depot gives psychiatrists a new adherence-friendly option alongside existing long-acting injectables of risperidone, paliperidone and aripiprazole. Pharmacy students should note the formulation science here -- depot delivery systems, sustained release and the pharmacokinetic flattening that makes once-monthly dosing possible are core concepts in pharmaceutics and biopharmaceutics.

WHO launches research toolkit for TB drug trials in pregnant and breastfeeding women

The World Health Organization on 13 October launched an online research toolkit that guides the inclusion of pregnant and breastfeeding women in tuberculosis drug and vaccine clinical trials. TB in pregnancy has long been an evidence desert: most trials excluded pregnant women, leaving clinicians with almost no data on safe, effective dosing for two lives at once.

India carries a large share of the global TB burden, and the Revised National TB Control Programme's goals depend on treating every patient safely -- including pregnant women. For pharmacy students, this toolkit is a powerful introduction to clinical trial ethics, ICH-GCP principles on vulnerable populations, and the pharmacokinetic changes of pregnancy (altered absorption, distribution, metabolism and excretion) that make dedicated dosing data essential. It is exactly the kind of regulatory-science story that strengthens answers in clinical pharmacy and pharmacovigilance exams.

China NMPA clears Phase II trial of GB268 trispecific antibody for colorectal cancer

China's National Medical Products Administration has cleared Edding Genor's Investigational New Drug application for a Phase II trial of GB268, a PD-1/CTLA-4/VEGF trispecific antibody, to be tested with chemotherapy as first-line treatment for advanced colorectal cancer.

Trispecific antibodies are the next frontier of cancer immunotherapy: one molecule that simultaneously blocks PD-1 and CTLA-4 immune checkpoints while neutralising VEGF-driven tumour blood vessel growth. Bispecifics are already reshaping oncology, and trispecifics like GB268 could compress three mechanisms into a single infusion. For pharmacy students tracking biologics, monoclonal antibodies and immuno-oncology, China's fast-moving pipeline -- and the NMPA's growing role as a global regulatory force -- is essential context for the future of biopharmaceuticals.

Conclusion

Today's news tells two clear stories. In India, the judiciary, the Health Ministry and a state government are converging on one theme: patients deserve to know exactly what their medicines and devices cost, and where the margins go. From the Supreme Court's stent-pricing question to Karnataka's QR-code complaint system, price transparency is moving from debate to enforcement -- and pharmacy students who understand DPCO, NPPA, MRP regulation and hospital pharmacy billing will be the professionals this new environment needs. Globally, the day belonged to genuine therapeutic innovation: the first new herpes mechanism in 30 years, a new monthly schizophrenia depot, better trial science for TB in pregnancy, and China's trispecific antibody push. Keep revising the mechanisms -- helicase-primase inhibition, long-acting injectable pharmacokinetics, checkpoint blockade -- because today's headlines are tomorrow's exam questions.

References

← All daily news